The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial
Open accessAbstract
BACKGROUND: There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors. METHODS: This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses. RESULTS: Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported. CONCLUSIONS: This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted. TRIAL REGISTRATION: NCT00490802.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have suggested that long-term oxytocin administration can alleviate the symptoms of autism spectrum disorder (ASD)”
From Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial (2016) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Small, randomized, controlled trials of intranasal oxytocin administered for 4 to 24 weeks in persons with autism spectrum disorder have had equivocal results with regard to oxytocin-associated improvements in social functioning, social cognition, or social attention.18–21”
From Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder (2021) · cites this paper as [21]
In the citing paper
“Multiple lines of evidence suggest an involvement of dysregulated neurotransmitter systems (serotonergic, oxytocinergic and dopaminergic systems) in autism.”
From Vitamin D and Autism Spectrum Disorder: A Literature Review (2016) · cites this paper as [181]
In the citing paper
“These systems play key roles in neurotransmission, brain maturation, cortical organisation and behaviours (including social behaviour and repetitive behaviour) [180,181,182,183,184].”
From Vitamin D and Autism Spectrum Disorder: A Literature Review (2016) · cites this paper as [181]
In the citing paper
“Clinical trials of OT in autistic patients are ongoing, yet several studies have produced inconclusive results (4–8)”
From Oxytocin under opioid antagonism leads to supralinear enhancement of social attention (2017) · cites this paper as [6]
In the citing paper
“This route of administration has been validated for both OT (6, 71) and NAL (72–74) in previous human studies”
From Oxytocin under opioid antagonism leads to supralinear enhancement of social attention (2017) · cites this paper as [6]
In the citing paper
“Clinical trials examining core symptoms of ASD have failed to consistently demonstrate efficacy of intranasal OT treatment (Anagnostou et al., 2012; Dadds et al., 2014; Guastella et al., 2015; Hollander et al., 2007)”
From Parallel social information processing circuits are differentially impacted in autism (2020) · cites this paper as Anagnostou et al., 2012
In the citing paper
“There have been generally positive results of OXT in adults with ASD, with trials showing improvements in repetitive behaviors, social reciprocity, and emotion recognition [75–77].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [75]
In the citing paper
“However, all these trials studied only short-term benefits (within a few weeks) of OXT administration.”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [75]
In the citing paper
“For example, oxytocin has been shown to increase gazing time on the eye region33, and to improve performance on the Reading the Mind in the Eyes Task in adults and adolescents with ASD48,49.”
From Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism (2021) · cites this paper as [49]
In the citing paper
“This pilot study suggested therapeutic potential with daily administration of IN-OT in this population of adults with ASD. This six-week study noted improvements in social cognition, quality of life, RRB, and some measures of emotional well-being with IN-OT, in essence, improvement in the core domains of ASD.”
From Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders (2014) · cites this paper as Anagnostou et al., 2012
In the citing paper
“Taken together, findings of these initial multiple-dose trials provided indications for a more consistent (positive) pattern of results for OT trials with adults with ASD [8–10], compared to trials with children with ASD [11–14].”
From Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up (2020) · cites this paper as [8]
In the citing paper
“Anagnostou et al. [8] assessed the safety and efficacy of 6 weeks of intranasal OT treatment on core autism symptom domains (social cognition/function and repetitive behaviors) in 19 adults with ASD (16 men, three women), and showed improved emotion recognition, quality of life, and tentative improvements in repetitive behaviors after OT treatment.”
From Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up (2020) · cites this paper as [8]
In the citing paper
“The initial sample size (n = 40) was set to be comparable to three prior studies showing significant effects of multiple-dose OT treatment on similar outcome measures [8, 9, 17].”
From Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up (2020) · cites this paper as [8]
In the citing paper
“In this view, it appears that beneficial effects of OT treatment on repetitive behaviors were mostly demonstrated in studies that adopted assessments based on self-reports (current study, [4, 8]), whereas no beneficial effects were evident in studies adopting informant-based reports of repetitive behavior [9–14].”
From Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up (2020) · cites this paper as [8]
In the citing paper
“Overall, these observed effects on repetitive behaviors are in line with previous trials with adult men with ASD showing beneficial effects of OT on repetitive behaviors after 4 h of intravenous OT administration [4] and after 6 weeks of daily administrations [8, 10].”
From Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up (2020) · cites this paper as [8]
In the citing paper
“Contrary to our findings, Anagnostou et al. [8] reported an OT-specific improvement in quality of life (socio-emotional section) after a 6-week treatment in adult men with ASD.”
From Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up (2020) · cites this paper as [8]
In the citing paper
“Second, in the current study, participants administered the OT nasal spray once a day (in the morning) while the majority of prior multiple-dose OT studies administered two doses/day (one in the morning and one in the afternoon) ([8–10, 12–14], but see [11]).”
From Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up (2020) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018486.91360.00 · Cited by 4,686
Baron‐Cohen, S., Wheelwright, S., Hill, J., Raste, Y., & Plumb, I. (2001) · Journal of Child Psychology and Psychiatry · doi:10.1111/1469-7610.00715 · Cited by 4,555 · cited 2×
“In the analysis of secondary measures, significant improvements were noted on the RMET – Revised (t = 3.91, df = 9.01, p = 0.004, Cohen’s d effect size = 1.2) and the WHOQOL – emotional (t = 2.42, df = 10.89, p = 0.034, Cohen’s d effect size = 0.84) (Table 2).”
MethodInfluentialBaron‐Cohen, S., Wheelwright, S. J., Hill, J., Raste, Y., & Plumb, I. (2001) · PubMed · Cited by 4,313
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690
Strong association of de novo copy number mutations with autism
Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C., Walsh, T., Yamrom, B., Yoon, S., Krasnitz, A., Kendall, J., et al. (2007) · Science · doi:10.1126/science.1138659 · Cited by 2,795
The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.
Kim, S.-W., Dysken, M., Pheley, A., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,333
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Research works printed but not linked: 1
- 10.1176/appi.neuropsych.23.3.332 · DOI
Cited by
Sorted by citations
Items 301–359 of 359
Coding Errors Lead to Unsupported Conclusions
Williams, D. E., & Bürkner, P. (2020) · Meta-Psychology · doi:10.15626/mp.2018.872 · Cited by 1
Tiefgreifende Entwicklungsstörungen
Warnke, A., & Taurines, R. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_83-1 · Cited by 1
Tiefgreifende Entwicklungsstörungen
Warnke, A., & Taurines, R. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_83 · Cited by 1
Oxytocin administration is a potential tool for behavioral management in felids
Burkhart, J. C., Heilbronner, S. R., & Packer, C. (2023) · Frontiers in Mammal Science · doi:10.3389/fmamm.2023.1148214 · Cited by 1
Tales from the life and lab of a female social neuroscientist
Parker, K. J. (2023) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2023.100202 · Cited by 1
Biochemical Biomarkers for Autism Spectrum Disorder
Anderson, G. M. (2014) · Wiley eBooks · doi:10.1002/9781118911389.hautc19 · Cited by 1
Scahill, L. D., Tillberg, C. S., & Martin, A. (2014) · Wiley eBooks · doi:10.1002/9781118911389.hautc23 · Cited by 1
Audunsdottir, K., Quintana, D. S., Westlye, L. T., Kang, H., Sartorius, A. M., Glaser, B. D., Andreassen, O. A., Nærland, T., Havdahl, A., Bøen, R., et al. (2023) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/8msku · Cited by 1
Social Behavior and Cultural Analysis: A Behavior Analytic Investigation
Lopez, C. R. (2024) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc2356188 · Cited by 1
Oxytocin Enhances Social-Emotional Reciprocity in AutismPreprint
Strobl, E. V. (2025) · medRxiv · doi:10.1101/2025.07.20.25331870 · Cited by 1
Multifaceted Roles of Oxytocin in Social Cognition and Social Decision-Making
Benedetti, A. (2025) · theses.fr (ABES) · doi:10.70675/be57db87z3a61z496bz8b5fz989b4449af9c · Cited by 1
Preclinical Testing of Novel Oxytocin Receptor Activators in Models of Autism Phenotypes
Jarstfer, M. B., Pedersen, C. A., & Moy, S. S. (2015)
Espino, C. C., & Vale-Martı́nez, A. (2015) · Revista de Neurología · doi:10.33588/rn.6109.2015219
Abdulamir, H. A., Al-Awadi, S. J. A., & Abdul‐Rasheed, O. F. (2016) · International Journal of Pharma and Bio Sciences
Future Directions in Psychopharmacology of Autism Spectrum Disorder
Mankad, D., & Anagnostou, E. A. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814602167_0019
Self-citationPhysiological correlates of emotion regulation in depersonalization disorder
Monde, K.-M. (2014) · CUNY Academic Works (City University of New York)
Gentili, G. (2016) · Padua@research (University of Padova)
Lefèvre, A. (2016) · theses.fr (ABES) · doi:10.70675/137893f0z4808z4aa8z9008z05c2a19b5144
da Silva, J. U. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.47.2017.tde-25072017-172834
Sexual Deprivation, Emotion, and Longevity: Neuropeptidergic Regulation of Aging in Drosophila
Harvanek, Z. M. (2018) · Deep Blue (University of Michigan)
On oxytocin and social behavior
Hovey, D. (2018) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Relações entre ocitocina, apego e sono em pessoas com Transtorno de Ansiedade Generalizada
Vale, E. A. N. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.47.2019.tde-16082019-110304
Oxitozina erabilgarria izan al daiteke autismoan gertatzen den urritasun sozialerako?
de Arechavaleta, C. R. D. M. R., Peñagarikano, O., & Erdozain, A. M. (2019) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.20886
DeMayo, M. M. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Benefits of Nonpharmacological and Pharmacological Treatments in Autistic Children
Cheng, A. (2019) · Dominican Scholar (Dominican University of California) · doi:10.33015/dominican.edu/2019.nurs.st.04
The Importance of Experimental Investigation of the CNS Oxytocin System
Boulton, K., & Guastella, A. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1759-5_4
A quinta directiva e a indemnizaçao dos danos corporais no espaço ibérico
Cardoso, T. D. (2008) · Revista española de seguros: Publicación doctrinal de Derecho y Economía de los Seguros privados
Ocytocine pour le traitement du trouble du spectre de l’autisme chez les enfants
Griffiths, J. L., Mishaal, R. A., Nabetani, M., & Goldman, R. D. (2022) · Canadian Family Physician · doi:10.46747/cfp.6802106
A Randomized Controlled Trial of Intranasal Oxytocin in Phelan-McDermid SyndromePreprint
Fastman, J., Foss‐Feig, J. H., Frank, Y., Halpern, D. B., Harony‐Nicolas, H., Layton, C., Sandin, S., Siper, P. M., Tang, L., Trelles, M. P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-268151/v1
Self-citationRaitez, S. R., Souza, T. P. D., Oliveira, R. T. D., Nascif, J. V. C., Culau, M. V., Teixeira, A. R., Orben, M. C., da Silva, F. D., Amaral, E. S., Brito, C. R., et al. (2023) · International Journal of Health Science · doi:10.22533/at.ed.15938923231010
The Love Hormone and Seizure Control: A Review of Oxytocin’s Impact on Epilepsy Management
Makhado, L., & Makhado, T. G. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112745
Chapter 66. Treatment of Autism Spectrum Disorder
Hegarty, J. P., & Hardan, A. Y. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as66
Oxytocinerge Modulation von Sprachproduktion
Vogt, C. E. C. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.86538
Perspectives d’avenir dans l’évaluation et le traitement des troubles du spectre de l’autisme
Smith, I. C., Pugliese, C. E., Corbett, B. A., & White, S. W. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-76574-2.00015-3
Oxytocin and Vasopressin in Autism and Genetic Syndromes
Levin‐Decanini, T., Francis, S. M., Sagar, A., Liu, W., Carter, C. S., & Jacob, S. (2015) · Contemporary clinical neuroscience · doi:10.1007/978-1-4939-2190-4_14
Yu, Y., Chaulagain, A., Pedersen, S. A., Lydersen, S., Leventhal, B. L., Szatmári, P., Aleksić, B., Ozaki, N., & Skokauskas, N. (2020) · Figshare · doi:10.6084/m9.figshare.11978739
Yu, Y., Chaulagain, A., Pedersen, S. A., Lydersen, S., Leventhal, B. L., Szatmári, P., Aleksić, B., Ozaki, N., & Skokauskas, N. (2020) · Figshare · doi:10.6084/m9.figshare.11978745
Fastman, J., Foss‐Feig, J. H., Frank, Y., Halpern, D., Harony‐Nicolas, H., Layton, C., Sandin, S., Siper, P. M., Tang, L., Trelles, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16714232
Self-citationFastman, J., Foss‐Feig, J. H., Frank, Y., Halpern, D., Harony‐Nicolas, H., Layton, C., Sandin, S., Siper, P. M., Tang, L., Trelles, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16714235
Self-citationDaniëls, N., Moerkerke, M., Steyaert, J. G., Bamps, A., Debbaut, E., Prinsen, J., Tang, T. Y., der Donck, S. V., Boets, B., & Alaerts, K. (2024) · Figshare · doi:10.6084/m9.figshare.26583870
Baker, E. J. (2023) · eScholarship (California Digital Library)
Lishaugen, H. T. S. (2017) · NORA - Norwegian Open Research Archives
Goodman, H. J., & Goodman, H. J. (2023) · UA Campus Repository (The University of Arizona)
Matějková, V. (2013) · Digital Library (University of West Bohemia)
Kosketuksen merkitys mielenterveyden tukemisessa : Satuhierontaa mielenterveyskuntoutujille
Heikkilä, S. (2018) · Theseus (Ammattikorkeakoulujen)
Kaushik, R., & Papendorp, C. M. (2026) · Oxford Journal of Student Scholarship · doi:10.65161/rec8kqrv0ahz44be2
Evenepoel, M., Daniëls, N., Moerkerke, M., Prinsen, J., Steyaert, J. G., Boets, B., Joossens, M., & Alaerts, K. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03964-0
Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials
Bonnieux, J. N., Gumuchian, S. T., Harboun, A., Trespalacios, F., Bélisle, K.-A., Haddad, A., Quintus-Bosz, O., McLellan, A., Chester-Trudel, L., Garred, D., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106749
Ikehara, M., Ishida, R., Yamamuro, K., Kashida, N., Takeda, T., Toritsuka, M., & Makinodan, M. (2026) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70138
Deilhaug, E., Moerkerke, M., Sartorius, A. M., Kang, H., Kildal, E. S.-M., Walle, K. M., Elvsåshagen, T., Westlye, L. T., Nærland, T., Andreassen, O. A., et al. (2026) · Psychophysiology · doi:10.1111/psyp.70334
Intranasal oxytocin modulates the social salience network in adult men with autismPreprint
Renström, J. G., Prinsen, J., Alaerts, K., & Choe, K. Y. (2026) · medRxiv · doi:10.64898/2026.08.24.26361211
Fang, G., Pan, W., Li, G., Ma, L., & Wei, J. (2026) · ALPHA PSYCHIATRY · doi:10.31083/ap45322
Galbiati, F., Wronski, M., Bitar, T., Bikas, A., Lamont, H., Hiranandani, S., Holman, K., Eddy, K. T., Asanza, E., Smith, S., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag291
Aspectos comportamentales de la oxitocina: su influencia en el estrés y en la cognición social
., P. M. (2014) · Cuadernos de neuropsicología
Metadata
- Authors
- Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., Wang, A. T., Pepa, L., Tanel, N., Kushki, A., & Hollander, E.
- Affiliations
- University of Toronto (CA)
- Rush University (US)
- St. John's University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Anagnostou, Evdokia
- ORCID
- Venue
- Molecular Autism
- Published
- 2012
- Volume
- 3
- Issue
- 1
- Pages
- 16
- ISSN
- 2040-2392 (ISSN-L)
- PMC
- PMC3539865
- OpenAlex
- W2134806674
- Cited by
- 350
- References
- 40
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 18 · 2023: 22 · 2022: 24 · 2021: 22 · 2020: 33 · 2019: 23 · 2018: 25 · 2017: 38 · 2016: 31 · 2015: 32 · 2014: 33 · 2013: 26 · 2012: 1
- FWCI
- 44.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Autism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Defense
- Ontario Brain Institute
- National Alliance for Research on Schizophrenia and Depression
- Holland Bloorview Kids Rehabilitation Hospital Foundation
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- intranasal oxytocin, autism spectrum disorder, autistic adults, social cognition, social functioning, repetitive behavior, quality of life, Reading the Mind in the Eyes Test, Yale-Brown Obsessive Compulsive Scale, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
